MAP2K1 and melanoma: MEK1/2 and PI3K/mTOR co-targeting is more effective than BRAF and PI3K/mTOR dual blockade in inhibition of signaling molecule phosphorylation in PLX4720-resistant and in cross-resistant melanoma cell lines